A plethora of tumour suppressor genes (tsg) have been shown to exist, some of which still await cloning (Fearon, 1997) . Loss of function of these genes is, as the name implies, tumorigenic. A central component of the Knudson model for this phenomenon is that loss of the gene is recessive, i.e. a single active allele is sucient to suppress the development of tumours. Nevertheless there have been hints of haploinsuciency in several tsg, culminating recently in two compelling reports regarding p53 and p27 Kip1 . This mini-review attempts to reconcile these observations with Knudson's model.
The best evidence in support of recessive loss of function of tsg (Knudson, 1971 (Knudson, , 1985 has been gathered for the Rb and Apc genes, the human homologues of which suppress the development of retinoblastomas and colon carcinomas respectively. Hemizygous mice for each of these genes are prone to tumours which can be detected at extremely early stages, while they are microscopic. In each case, semiquantitative PCR analysis has demonstrated that both alleles of the tsg are already inactivated, implying loss of function of the second allele is rate-limiting for initiation of the tumour (Nikitin and Lee, 1996; Levy et al., 1994) .
There are two types of observation which are consistent with, but not proof of, recessive loss, and have been so widespread as to become de facto criteria for tsg de®nition. The ®rst is that human germline inactivation has occurred, resulting in cancer-prone families (reviewed by de la Chapelle and Peltomaki, 1998). For several of the genes, this has been con®rmed using hemizygous mice (reviewed by McClatchey and Jacks, 1995) . The second observation is that in macroscopic tumours, whether from members of cancer-prone families or sporadic cases, loss of tsg function is also frequently found to be bi-allelic (Knudson, 1993) . The apparent exceptions (i.e. hemizygous loss) have often been dismissed without thorough investigation, since inactivating mutations can be subtle and regulatory regions extensive, and since dominant negative mutants have been described for two tsg (Jenkins et al., 1984; Hastie, 1994) . As discussed below, both hereditary mutations and biallelic loss can also be consistent with haploinsuciency, and neither is an obligate property of a tsg.
There are reports in the literature for several tsg, namely Nf1 (Jacks et al., 1994) , p27
Kip1 (Pietenpol et al., 1995 ), Msh2 (de Wind et al., 1998 , Pten (Podsypanina et al., 1999) , Tsc2 (Kobayashi et al., 1999) , CBFA2 (Song et al., 1999) and p53 (Nigro et al., 1989; Mulligan et al., 1990; Davido et al., 1991; Sedlacek et al., 1998) , of tumours retaining a single possibly active allele. But by far the strongest evidence of this kind is for haploinsuciency of p53 and p27 Kip1 in hemizygous mice, where the potential complication of dominant negative mutations has been excluded (Venkatachalam et al., 1998; Fero et al., 1998) .
p53 is one of the prototypical tsg, and the most frequently mutated gene in human cancers (Greenblatt et al., 1994) . In the study by Venkatachalam et al. (1998) , the penetrance of spontaneous tumours in p53+/7 mice was 95%, with a median age of morbidity of 460 days. Less than half of the tumours had lost the wild-type allele: these tumours showed greater chromosomal instability, and presumably because of this, tended to appear earlier. Nevertheless, approximately 50% of the tumours harvested before 550 days, and 85% of the late-arising tumours, retained one expressed allele. By contrast, tumour incidence in p53+/+ mice was only 20%, with a much longer median onset, of approximately 700 days.
The alleles retained in two of the p53+/7 tumours were completely sequenced in the coding region, and found to be wild-type. Five tumours were examined in a wide range of tests of p53 function, namely radiationinduced apoptosis, binding to the p53 response element DNA, maintenance of genomic stability, and transcriptional regulation of p53 targets, viz activation of p21
Waf1 and mdm2 and inactivation of PCNA. All of these results were consistent with the presence of a functional p53 protein, as were the Western blot data. So the evidence suggests that fatally malignant tumours retaining the wild-type p53 allele appear slightly later than tumours which have lost it, but signi®cantly more frequently and earlier than tumours in the +/+ mice.
This insuciency for tumour suppression is consistent with earlier reports of haploinsuciency of p53 in its normal cell functions in response to induction by radiation: stimulation of apoptosis in Oncogene (2000) 19, 3434 ± 3438 normal thymocytes and large intestine (Clarke et al., 1993 (Clarke et al., , 1994 , and transcriptional activation of the mdm2 promoter in embryos (Gottlieb et al., 1997) . It is implied that although p53 hemizygous cells respond to DNA damage signals, the eciency of the response is lower, allowing some cells to escape and continue to proliferate, and thus become targets for further mutations in other genes.
The tsg status of the p27 Kip1 gene has been in doubt because neither homozygous loss in human tumours nor familial mutations have emerged (Pietenpol et al., 1995) . Nevertheless, there is abundant evidence of its important role as a cell cycle kinase inhibitor, and some evidence that its loss is tumorigenic (Coats et al., 1996; Kato et al., 1994; Nourse et al., 1994; .
In the study by Fero et al. (1998) , 32% of mice hemizygous for p27
Kip1 were shown to develop tumours: despite a relatively late onset (median 570 days), all arose before any appeared in the +/+ control mice. None of the tumours examined showed loss of the second allele, whose sequence was shown to be wildtype (complete coding regions sequenced from one spontaneous tumour and from 13 tumours induced by radiation or ethyl nitrosourea). The gene product was expressed at levels comparable to those of normal tissues, and was appropriately localized to the nucleus. This argues that p27
Kip1 is not only a tsg, but is truly haploinsucient.
It is important to note that for both p53 and p27
Kip1
, loss of two alleles was more tumorigenic than loss of one. Tumours arose more quickly in homozygous than hemizygous de®cient mice (Venkatachalam et al., 1998; Fero et al., 1998) . In addition, in the hemizygous p53 mice, as mentioned above, tumours which had lost the second allele arose more quickly than those which had not (Venkatachalam et al., 1998) . So the haploinsuciency in each case was incomplete. Instead of a clear threshold of protein expression, above which full function is achieved, there must be a gradient, with expression from a single allele intermediate between fully sucient and completely ineective, as depicted in Figure 1a . By contrast, embryonic development proceeds normally even in the complete absence of the respective gene (Donehower et al., 1992; Nakayama et al., 1996; Kiyokawa et al., 1996; Fero et al., 1996) . This is also depicted in Figure 1a .
In principle, the shape of these gradients, and the positions on them of the haploid expression level could be dierent for each function of each protein, and for each cell type in which it is expressed. This notion is supported by the data from other gene knockouts. Figure 1b refers to Rb-de®cient mice expressing various levels of human RB from a transgene: whereas less than 20% of the normal haploid level seems to suce to suppress tumorigenicity in the mouse pituitary gland, approximately 100% is needed to allow development of the embryo (Chang et al., 1993) . A third pattern may be exempli®ed by Cbfa2 (Figure 1c) , one copy of which is sucient for development (Okuda et al., 1996) , though not for full megakaryopoiesis and possibly not for tumour suppression (Song et al., 1999; Wang et al., 1996) . Figure 1 highlights the fact that there will be selective pressure for loss of function of both alleles in each case. The only tsg which would not be susceptible would be a completely haploinsucient gene.
In order to accommodate haploinsuciency into a unifying model for tsg loss, two further parameters need to be taken into account. The advantage conferred by loss of function of each tsg allele must also depend on the strength of the biochemical eect, i.e. the relative selective advantage, of each loss as measured by relative increase in growth rate, resistance Kinzler and Vogelstein (1997) have classi®ed tsg into so-called gatekeepers (directly controlling cell cycle) and caretakers (maintaining the integrity of the genome). It is agreed that loss of caretaker tsg function could be selected at any time during the course of tumorigenesis. It has been proposed that loss of gatekeeper function is an initiating event. Though this has been demonstrated for Rb and Apc, it is evident that other losses are consistently selected at later stages (Fearon and Vogelstein, 1990) , suggesting the notion of a series of physiological`gates' through which a tumour passes in becoming malignant. For example, in simplistic terms, one would predict selection for losses which prevent exogenously-induced apoptosis to occur preferentially in the early stages of tumour development, when the tumour mass is low. By contrast, losses facilitating vascularization or metastasis would be selected in intermediate and late stages respectively.
The combined eects of these three parameters can be described as follows:
(1) Where loss of a given tsg confers a strong selective advantage early in tumour development, both alleles can be inactivated, either because the loss is recessive, e.g. RB and APC, or because the haploinsuciency of the tsg is incomplete. It may be that NF1 ®ts the latter category, at least for some tumour types (Jacks et al., 1994; Shannon et al., 1994) . (2) The weaker the selective advantage conferred by the loss, and the later in the course of tumour development, the less opportunity there will be for homozygous loss. So weak and late-acting losses will only be eective if the tsg is haploinsucient. Examples are p27
Kip1 and the suppressor of metastasis CD82 (Dong et al., 1996) . (3) Between these two extremes, there will be haploinsucient tsg which are lost homozygously in some tumours and hemizygously in others, depending on the interactions between the stochastic occurrence of chromosomal lesions and other in¯uences on the physiology and growth of the individual emerging tumour. Examples are p53, loss of which could be as much as 50% hemizygous (Nigro et al., 1989; Mulligan et al., 1990; Davido et al., 1991; Sedlacek et al., 1998) , and DCC, most often hemizygous (Cho et al., 1994) . (4) With regard to familial cancer, germline tsg mutations conferring the strongest and earliestacting selective advantage will be most easily detected, regardless of haploinsuciency. Mutations whose eects are latest-acting and weakest will still occur and be carried in the germline, but will be less easily detected because they will neither raise the incidence nor accelerate the onset of tumours dramatically above background sporadic values.
It is well established that many tsg are not required at all for normal development. Loss of function mutations in haploinsucient tsg of this kind could be transmitted through the germline. Indeed if the work reviewed above is accurate, p53 is one example. Even for genes which are necessary for development, haploinsuciency for tumorigenesis need not be an impediment to germline transmission of mutations, if the levels of protein necessary for development are lower than the levels needed for protection from tumours. As described above and depicted in Figure 1c , there is preliminary evidence that this is true for CBFA2 (Song et al., 1999; Okuda et al., 1996; Wang et al., 1999) . In summary, the spectrum of patterns of tsg loss can be explained by the combined eects of three continuous and independent parameters, so that tsg which are haploinsucient, or whose loss confers a weak selective advantage, or takes eect late in the development of the tumour will tend to be lost hemizygously, as depicted in Figure 2 . The last two properties will also tend to prevent detection of germline mutations.
Among other putative tsg, there are four important to leukaemia, lying at 5q (Zhao et al., 1997) , 7q (Tosi et al., 1999), 20q (Asimakopoulos and Green, 1996) and 11p11-12, by virtue of its synteny with mouse Figure 2 Dependence of zygosity of loss of function of tsg alleles on three continuous and independent parameters. Haplosuciency of tsg, and strong and early eects of loss of their function during tumour development will promote homozygous loss, whereas haploinsuciency, and weak and late eects of loss will promote hemizygous loss chromosome 2 (Alexander et al., 1995; Silver et al., 1999) . Somatic losses of the tsg at 5q and 7q tend to occur late in tumour development, often as a consequence of therapy for a pre-existing malignancy (Johansson et al., 1994; Pedersen-Bjergaard et al., 1995) . The eect of loss of the 20q gene is apparently weak (Greenberg et al., 1997) , and no familial cases have been reported for this or for the gene at 11p11-12. It follows that loss of function of all of these tsg in sporadic tumours will be predominantly hemizygous. However, there are rare familial cases of leukaemia which consistently show somatic deletion of 5q (Olopade et al., 1996) . Only these tumours can be predicted with con®dence to bear a single inherited mutant copy of the tsg.
